Primarily representing clients in the tech, biopharmaceuticals, and healthcare sectors, the ‘talented team’ at Fenwick & West LLP advises on executive compensation and benefit arrangements relating to acquisitions and public securities offerings. Silicon Valley-based Shawn Lampron spearheads the group, advising emerging growth companies, investors, and public entities on equity compensation and ERISA-related matters during transactions. In New York, Matthew Cantor offers expertise on issues such as Section 409A deferred compensation and Section 280G golden parachute payments. Elizabeth Gartland, based in Santa Monica, counsels technology companies on compensation-related compliance in M&A, IPOs, and corporate governance contexts. Silicon Valley’s Marshall Mort addresses equity and executive compensation-related tax, securities, and accounting challenges, while Nancy Chen assists both start-ups and established public companies with their compensation needs.
Testimonials
Collated independently by Legal 500 research team.
‘Their people are a great asset to Fenwick & West as they are knowledgeable, kind and explain things very well to their clients. They are extremely knowledgeable on all areas of their practice and provide practical advice.’
‘The partners are always copied on emails as well as in attendance for calls but allow the engagements to be run by associates, under guidance. In the years that I have worked with them I have seen many associates vastly improve their skill sets, increase their knowledge base and get to move on to many different types of projects and issues, and therefore move up within the firm. I am always impressed with the caliber of individuals that they hire.’
Key clients
- Cisco Systems
- Chinook Therapeutics
Work highlights
- Represented Chinook Therapeutics, Inc. in its acquisition by Novartis AG for up to $3.5 billion.
- Represented DICE Therapeutics, Inc. in its acquisition by Eli Lily and Company for $2.4 billion.